Research programme: psychotic disorder therapeutics - Clera

Drug Profile

Research programme: psychotic disorder therapeutics - Clera

Alternative Names: CLR 100 series; CLR 136; CLR 151; CLR 155; CLR 161; Schizophrenia therapeutics - Clera

Latest Information Update: 21 Jan 2014

Price : $50

At a glance

  • Originator Clera
  • Class Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Psychotic disorders; Schizophrenia

Most Recent Events

  • 21 Jan 2014 Research programme: psychotic disorder therapeutics - Clera is available for licensing as of 01 Jan 2014.
  • 01 Jan 2014 Preclinical trials in Psychotic disorders in Canada (PO)
  • 18 Jan 2011 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top